Advanced search
Publication Cover
The American Journal of Drug and Alcohol Abuse
Encompassing All Addictive Disorders
Volume 19, 1993 - Issue 3
Submit an article Journal homepage
410
Views
63
CrossRef citations to date
0
Altmetric
Original Article

Toward a Comparative Overview of Dependence Potential and Acute Toxicity of Psychoactive Substances Used Nonmedically

Robert S. Gable Faculty in Psychology, The Claremont Graduate School Claremont, California, 91711-6175
Pages 263-281 | Published online: 07 Jul 2009

Citations (63)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Tamonud Modak, Roshan Bhad & Ravindra Rao. (2019) A rare case of physical dependence with psychedelic LSD - A case report. Journal of Substance Use 24:4, pages 347-349.
Read now
Mark Haden, Brian Emerson & Kenneth W. Tupper. (2016) A Public-Health-Based Vision for the Management and Regulation of Psychedelics. Journal of Psychoactive Drugs 48:4, pages 243-252.
Read now
Pranveer Singh & Jason Luty. (2013) Clients of drug and alcohol services: more fearful of heroin than members of the general public?. Journal of Substance Use 18:3, pages 221-228.
Read now
Harris Friedman. (2006) The Renewal of Psychedelic Research: Implications for Humanistic and Transpersonal Psychology. The Humanistic Psychologist 34:1, pages 39-58.
Read now
RobertS. Gable. (2004) Acute Toxic Effects of Club Drugs. Journal of Psychoactive Drugs 36:3, pages 303-313.
Read now
Michele D. Kipke, Susanne B. Montgomery, Thomas R. Simon & Ellen F. Iverson. (1997) “Substance Abuse” Disorders among Runaway and Homeless Youth. Substance Use & Misuse 32:7-8, pages 969-986.
Read now
Richard P. Mattick & Shane Darke. (1995) Drug replacement treatments: Is amphetamine substitution a horse of a different colour?. Drug and Alcohol Review 14:4, pages 389-394.
Read now

Articles from other publishers (56)

Joseph J. Palamar, Nicole D. Fitzgerald, David J. Grundy, Joshua C. Black, Jennifer S. Jewell & Linda B. Cottler. (2022) Characteristics of poisonings involving ketamine in the United States, 2019–2021. Journal of Psychopharmacology 37:8, pages 802-808.
Crossref
Joseph J. Palamar & Austin Le. (2023) Prevalence of self-reported adverse effects associated with drug use among nightclub and festival attendees, 2019–2022. Drug and Alcohol Dependence Reports 7, pages 100149.
Crossref
Luis Henríquez-Hernández, Jaime Rojas-Hernández, Domingo Quintana-Hernández & Lucas Borkel. (2023) Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?—A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines. Toxics 11:2, pages 148.
Crossref
Chris MeyersChris Meyers. 2023. Drug Legalization. Drug Legalization 25 52 .
Alexander N. Melinyshyn & Farnaz Amoozegar. (2021) Cannabinoid Use in a Tertiary Headache Clinic: A Cross-Sectional Survey. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 49:6, pages 781-790.
Crossref
V. L. Matrenitsky. (2022) РЕНЕСАНС ПСИХОДЕЛІЧНОЇ ТЕРАПІЇ ТА ЇЇ ЗНАЧЕННЯ ДЛЯ УКРАЇНИ. Likarska sprava:3-4, pages 37-59.
Crossref
Teresa Reynolds Sousa, João Rema, Sergio Machado & Filipa Novais. (2022) Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets. Current Topics in Medicinal Chemistry 22:15, pages 1250-1260.
Crossref
Anne K Schlag, Jacob Aday, Iram Salam, Jo C Neill & David J Nutt. (2022) Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology 36:3, pages 258-272.
Crossref
Gregory S. Carter. 2022. Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy. Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy.
Sindhu Ramesh, Kruthi Gopal, Jack Deruiter, Payton Lowery, Manoj Govindarajulu, Suhrud Pathak, Rishi Nadar, Dinesh Chandra Agrawal & Muralikrishnan Dhanasekaran. 2022. Cannabis/Marijuana for Healthcare. Cannabis/Marijuana for Healthcare 155 172 .
David B. Yaden, Andrea P. Berghella, Paul S. Regier, Albert Garcia-Romeu, Matthew W. Johnson & Peter S. Hendricks. (2021) Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. International Journal of Drug Policy 98, pages 103380.
Crossref
Henry Lowe, Ngeh Toyang, Blair Steele, Henkel Valentine, Justin Grant, Amza Ali, Wilfred Ngwa & Lorenzo Gordon. (2021) The Therapeutic Potential of Psilocybin. Molecules 26:10, pages 2948.
Crossref
Bijo Mathew, Seetha Harilal, Arafa Musa, Rajesh Kumar, Della Grace Thomas Parambi, Jobin Jose, Md. Sahab Uddin, Muhammad Ajmal Shah, Tapan Behl & Mazhuvancherry Kesavan Unnikrishnan. (2021) An Agathokakological Tale of Δ9-THC: Exploration of Possible Biological Targets. Current Drug Targets 22:7, pages 823-834.
Crossref
Alan K. Davis, Frederick S. Barrett, Darrick G. May, Mary P. Cosimano, Nathan D. Sepeda, Matthew W. Johnson, Patrick H. Finan & Roland R. Griffiths. (2021) Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry 78:5, pages 481.
Crossref
Bradley J. Vivace, Allyson N. Sanders, Steven D. Glassman, Leah Y. Carreon, Joseph L. Laratta & Jeffrey L. Gum. (2021) Cannabinoids and orthopedic surgery: a systematic review of therapeutic studies. Journal of Orthopaedic Surgery and Research 16:1.
Crossref
Kylie O'Brien & Philip BlairKylie O’Brien & Philip Blair. 2021. Medicinal Cannabis and CBD in Mental Healthcare. Medicinal Cannabis and CBD in Mental Healthcare 513 557 .
John C. Dearden. (2020) Rodent LD50 Tests. International Journal of Quantitative Structure-Property Relationships 5:3, pages 1-5.
Crossref
Juan José Fuentes, Francina Fonseca, Matilde Elices, Magí Farré & Marta Torrens. (2020) Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. Frontiers in Psychiatry 10.
Crossref
Jamie L. Flexon, Lisa Stolzenberg & Stewart J. D'Alessio. (2019) The effect of cannabis laws on opioid use. International Journal of Drug Policy 74, pages 152-159.
Crossref
Christopher B. Germann. (2019) 5-Methoxy-N,N-dimethyltryptamine: An Ego-Dissolving Endogenous Neurochemical Catalyst of Creativity. Activitas Nervosa Superior 61:4, pages 170-216.
Crossref
John C. Dearden. (2019) Prediction of Human Lethality of Psychoactive Drugs From Rodent LD50 Values. International Journal of Quantitative Structure-Property Relationships 4:2, pages 1-27.
Crossref
Zuzana Postránecká, Čestmír Vejmola & Filip Tylš. (2019) Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal?. Journal of Psychedelic Studies 3:1, pages 19-31.
Crossref
Linda Matua, Guido Muharremi, Elizana Petrela, Mirnela Koçibelli, Gentian Vyshka & Bledar Xhemali. (2019) The Use of Psychoactive Substances and Illegal Drugs in the Albanian Society. Current Drug Research Reviews 11:1, pages 73-79.
Crossref
Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks & Jack E. Henningfield. (2018) The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology 142, pages 143-166.
Crossref
Andy Whelan & Mark I Johnson. (2018) Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?. Pain Management 8:3, pages 217-229.
Crossref
David E. Nichols & Charles S. Grob. (2018) Is LSD toxic?. Forensic Science International 284, pages 141-145.
Crossref
Brian Eastwood, John Strang & John Marsden. (2017) Effectiveness of treatment for opioid use disorder: A national, five-year, prospective, observational study in England. Drug and Alcohol Dependence 176, pages 139-147.
Crossref
Peter S. Hendricks & Charles S. Grob. 2017. Rational Suicide in the Elderly. Rational Suicide in the Elderly 203 210 .
Claudia Baumung, Jürgen Rehm, Heike Franke & Dirk W. Lachenmeier. (2016) Comparative risk assessment of tobacco smoke constituents using the margin of exposure approach: the neglected contribution of nicotine. Scientific Reports 6:1.
Crossref
Saibal Das, Preeti Barnwal, Anand Ramasamy, Sumalya Sen & Somnath Mondal. (2016) Lysergic acid diethylamide: a drug of ‘use’?. Therapeutic Advances in Psychopharmacology 6:3, pages 214-228.
Crossref
Shaunna L. Clark, Nathan A. Gillespie, Daniel E. Adkins, Kenneth S. Kendler & Michael C. Neale. (2016) Psychometric modeling of abuse and dependence symptoms across six illicit substances indicates novel dimensions of misuse. Addictive Behaviors 53, pages 132-140.
Crossref
Michael P. Bogenschutz & Matthew W. Johnson. (2016) Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology and Biological Psychiatry 64, pages 250-258.
Crossref
T. Buchborn, G. Grecksch, D.C. Dieterich & V. Höllt. 2016. Neuropathology of Drug Addictions and Substance Misuse. Neuropathology of Drug Addictions and Substance Misuse 846 858 .
C. Lindsay DeVane. 2016. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents 247 266 .
Esa R. Korpi, Bjørnar den Hollander, Usman Farooq, Elena Vashchinkina, Ramamoorthy Rajkumar, David J. Nutt, Petri Hyytiä & Gavin S. Dawe. (2015) Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse. Pharmacological Reviews 67:4, pages 872-1004.
Crossref
Peter S Hendricks, Matthew W Johnson & Roland R Griffiths. (2015) Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology 29:9, pages 1041-1043.
Crossref
Eric P. Baron. (2015) Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …. Headache: The Journal of Head and Face Pain 55:6, pages 885-916.
Crossref
Dirk W. Lachenmeier & Jürgen Rehm. (2015) Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Scientific Reports 5:1.
Crossref
William A. Richards. (2014) HERE AND NOW: DISCOVERING THE SACRED WITH ENTHEOGENS. Zygon® 49:3, pages 652-665.
Crossref
Zafar Alam Mahmood. 2013. Natural Products. Natural Products 523 552 .
Cameron Adams. (2010) Psychedelics and holistic thinking: a tool for science. Drugs and Alcohol Today 10:1, pages 33-35.
Crossref
MW Johnson, WA Richards & RR Griffiths. (2008) Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology 22:6, pages 603-620.
Crossref
M. Soyka. 2008. Psychiatrie und Psychotherapie. Psychiatrie und Psychotherapie 1189 1243 .
M. Soyka. 2008. Psychiatrie und Psychotherapie. Psychiatrie und Psychotherapie 1145 1188 .
David Nutt, Leslie A King, William Saulsbury & Colin Blakemore. (2007) Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet 369:9566, pages 1047-1053.
Crossref
William A. Richards. (2005) Entheogens in the Study of Religious Experiences: Current Status*. Journal of Religion and Health 44:4, pages 377-389.
Crossref
Floris A. de Jong, Frederike K. Engels, Ron H.J. Mathijssen, Lia van Zuylen, Jaap Verweij, Remco P.H. Peters & Alex Sparreboom. (2005) Medicinal Cannabis in Oncology Practice: Still a Bridge Too Far?. Journal of Clinical Oncology 23:13, pages 2886-2891.
Crossref
Nancy Darling, Raymond F. Palmer & Michele D. Kipke. (2005) Do street youths' perceptions of their caregivers predict HIV-risk behavior?. Journal of Family Psychology 19:3, pages 456-464.
Crossref
M. Soyka. 2003. Psychiatrie und Psychotherapie. Psychiatrie und Psychotherapie 1005 1047 .
Nicholas Seivewright & Olawale Lagundoye. (2018) What the clinician needs to know about magic mushrooms. Advances in Psychiatric Treatment 6:5, pages 344-347.
Crossref
Alice A. Gleghorn, Rani Marx, Eric Vittinghoff & Mitchell H. Katz. (1998) Association between drug use patterns and HIV risks among homeless, runaway, and street youth in Northern California. Drug and Alcohol Dependence 51:3, pages 219-227.
Crossref
Libby Topp & Shane Darke. (1997) The applicability of the dependence syndrome to amphetamine. Drug and Alcohol Dependence 48:2, pages 113-118.
Crossref
Robert S. Gable. (1997) Toxicity of a Gourmet Banquet. Journal of Drug Issues 27:4, pages 703-712.
Crossref
Robert S. Gable. (1997) Opportunity costs of drug prohibition. Addiction 92:9, pages 1179-1182.
Crossref
LIBBY TOPP & RICHARD P. MATTICK. (2006) Validation of the amphetamine dependence syndrome and the SAmDQ. Addiction 92:2, pages 151-162.
Crossref
ROBERT S. GABLE. (2008) Regulatory Risk Management of Psychoactive Substances. Law & Policy 14:4, pages 257-276.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.